From the Guidelines
Onyfix contains the active ingredient denosumab, a human monoclonal antibody used in the treatment of bone diseases such as multiple myeloma. The evidence from the NCCN Guidelines for MM [ 1 ] supports the use of denosumab as a bone-modifying agent for patients with symptomatic multiple myeloma, regardless of documented bone disease. Denosumab is preferred in patients with renal disease due to its lower rates of renal toxicity compared to bisphosphonates [ 1 ].
Some key points to consider when using denosumab include:
- The need for a baseline dental examination and monitoring for osteonecrosis of the jaw (ONJ) [ 1 ]
- Monitoring for renal dysfunction and hypocalcemia [ 1 ]
- The recommended duration of therapy is up to 2 years, with continuation beyond 2 years based on clinical judgement [ 1 ]
- The frequency of dosing (monthly vs every 3 months) depends on individual patient criteria and response to therapy [ 1 ]
It is essential to note that denosumab has equivalent benefits to zoledronic acid in reducing skeletal-related events and improving overall survival in patients with multiple myeloma [ 1 ]. However, denosumab has a higher rate of ONJ compared to clodronate, although the difference was not statistically significant when compared to zoledronic acid [ 1 ].
From the Research
Active Drug Information
- The active drug Onyfix is not mentioned in the provided studies 2, 3, 4, 5, 6.
- The studies primarily discuss the use of bortezomib, lenalidomide, and thalidomide in the treatment of multiple myeloma.
- There is no information available on Onyfix in the given evidence.
Related Drug Information
- Bortezomib is a proteasome inhibitor used in the treatment of multiple myeloma 2, 3, 5, 6.
- Lenalidomide is an immunomodulatory drug used in the treatment of multiple myeloma 2, 4, 6.
- Thalidomide is an immunomodulatory drug used in the treatment of multiple myeloma 2, 4, 5, 6.
- Carfilzomib is a second-generation proteasome inhibitor used in the treatment of relapsed and refractory multiple myeloma 4.
Study Findings
- The studies discuss the efficacy and safety of various drug combinations in the treatment of multiple myeloma 2, 3, 6.
- The findings suggest that certain drug combinations, such as RD and VRDc, may increase overall survival and progression-free survival in patients with multiple myeloma 6.
- However, these combinations may also increase the risk of adverse events, such as polyneuropathies and serious adverse events 6.